Galectin Therapeutics INC Form 4 insider transactions

Richard E Uihlein, a Director and 10% owner of Galectin Therapeutics Inc, reported multiple transactions in common stock on July 31, 2026.

Khurram Jamil, Chief Medical Officer of Galectin Therapeutics Inc, sold 16,250 shares of common stock on July 14, 2026 for $5.13 per share.

Galectin Therapeutics Director Harold Shlevin executed trades under a pre-arranged 10b5-1 plan, selling shares and exercising stock options.

Galectin Therapeutics Chief Medical Officer Jamil Khurram reported transactions involving the sale of common stock and the exercise of stock options under a pre-arranged trading plan.

Galectin Therapeutics reports that Chief Medical Officer Jamil Khurram sold 7,557 shares of common stock under a pre-arranged trading plan.

Chief Medical Officer Jamil Khurram exercised 568 stock options and sold the resulting shares under a Rule 10b5-1 plan.

Galectin Therapeutics director Henry Brem received a grant of 60,000 stock options with an exercise price of $3.16, vesting fully by December 31, 2026.

Galectin Therapeutics Inc. Director Kary Eldred reported the purchase of 300 shares of common stock at $2.70 per share.

Galectin Therapeutics CEO Joel Lewis filed an amended Form 4 to correct the number of common stock options granted on January 16, 2026, to 91,000 at an exercise price of $3.04.

Galectin Therapeutics Director Benjamin Sr. Carson was granted 60,000 stock options with an exercise price of $3.04, vesting fully by December 31, 2026.

Galectin Therapeutics Director Richard A. Zordani Jr. was granted 60,000 stock options with an exercise price of $3.04, vesting fully by December 31, 2026.

Galectin Therapeutics' Chief Medical Officer, Khurram Jamil, received new equity awards including 65,000 stock options and 100,000 restricted stock units.

Galectin Therapeutics Director Kevin D. Freeman was granted 60,000 stock options with an exercise price of $3.04, vesting fully on December 31, 2026.

Galectin Therapeutics Director Kary Eldred was granted 60,000 stock options with an exercise price of $3.04, vesting fully by December 31, 2026.

Galectin Therapeutics Inc. CEO Joel Lewis was granted 84,000 stock options and 120,000 restricted stock units, aligning executive incentives with shareholder value.

Galectin Therapeutics' Chief Financial Officer, Jack W. Callicutt, was granted 65,000 stock options and 100,000 restricted stock units as part of his compensation.

Galectin Therapeutics Director Harold H. Shlevin was granted 60,000 stock options with an exercise price of $3.04, vesting fully by December 31, 2026.

Galectin Therapeutics director Gilbert S. Omenn was granted 60,000 stock options vesting in December 2026.

Galectin Therapeutics Director Gilbert F. Amelio was granted 60,000 stock options with an exercise price of $3.04, vesting fully by December 31, 2026.

Galectin Therapeutics Director Elissa J. Schwartz was granted 60,000 stock options with an exercise price of $3.04, vesting fully by December 31, 2026.

Richard E. Uihlein, a Director and 10% owner of Galectin Therapeutics, acquired 13,158 restricted common shares and 60,000 stock options.

Galectin Therapeutics CEO Joel Lewis reported the settlement of deferred stock units and shares withheld for tax purposes, executed under a Rule 10b5-1 plan.

Galectin Therapeutics Inc. CEO Joel Lewis reported the vesting of 84,000 Restricted Stock Units and subsequent sales of an equal number of common shares under a pre-arranged 10b5-1 plan.

Galectin Therapeutics CFO Jack W. Callicutt reported the sale of common stock following the vesting of restricted stock units under a pre-arranged 10b5-1 plan.

Galectin Therapeutics' Chief Medical Officer, Khurram Jamil, sold 60,000 shares of common stock in early January 2026, following the vesting of Restricted Stock Units, as part of a pre-arranged 10b5-1 plan.

Galectin Therapeutics' Chief Medical Officer, Khurram Jamil, exercised stock options and immediately sold 8,125 shares of common stock for a weighted average price of $4.0725 per share.

Galectin Therapeutics Director Kevin D. Freeman reported a planned acquisition of 5,500 shares of common stock at $3.548 per share on December 23, 2025.

Galectin Therapeutics Director Kevin D. Freeman plans to acquire 5,500 shares of common stock at $3.548 per share under a Rule 10b5-1 plan.

Kary Eldred, a Director at Galectin Therapeutics Inc., reported the acquisition of 700 shares of common stock at $3.73 per share.

A director at Galectin Therapeutics Inc. has acquired 5,500 shares of common stock through a pre-planned transaction.